Original document(29 pages)  中文版
    The present invention relates to the application of diosgenin in preparing medicine with synergistic attenuation on chemotherapeutic medicine, and belongs to the field of new use of diosgenin. Diosgenin has synergistic attenuation effect on chemotherapeutic medicine for human melanoma, cervical carcinoma, gastric carcinoma and mammary cancer, and may be used to cooperate with chemotherapeutic medicine so as to generate synergism and attenuation effects. The present invention can reduce the dosage of chemotherapeutic medicine and decrease the toxic side effect of chemotherapeutic medicine.
Application Number
申请号		 200610017243 Application Date
申请日		 2006.10.13
Title 名称 Application of diosgenin in preparing medicine with synergistic attenuation
Publication Number
公开号		 1931173 Publication Date
公开日		 2007.03.21
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K31/58;A61P35/00;C07J71/00
Applicant(s) Name
申请人		 Jilin Tianyao Sci-Tech Co., Ltd.
Address 地址
Inventor(s) Name 发明人
Attorney & Agent 代理人 weizheng ji
More information 更  多  信  息


 Related patents information
Pharmaceutical usage of diosgenin
Application of evodiamine in the preparation of medicine
Echinocystic acid preparation method、medicinal preparation and new use as medicine
Medicine for relieving spasm and pain and preparation process thereof
Medicine containing ginsenoside Rh1 and its new application
Process for extracting triterpenic acid from gleditschia, and medical use and Chinese medicine of triterpenic acid
Application of hederagenin in preparing anihyperlipemia medicine
Antitumor use of diosgenin
Anti-infection medicine
Medicine compound for preventing and treating gynecopathy such as pelvic inflammatory disease
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.